OR WAIT 15 SECS
Regulations and business changes have altered Big Pharma’s place in the industry.
Chris Moreton, PhD, partner at FinnBrit Consulting and a member of PharmTech’s Editorial Advisory Board, discusses how the role of Big Pharma has changed over the years and the positive effects of regulations.
PharmTech: During your 40 years in the pharmaceutical industry, how has it evolved? What advances have been made? What were some factors that hindered advances?
Moreton: Industry has evolved in several ways. For example, in the early 1970s, Big Pharma was the center for drug discovery and innovation. That is no longer the case, and it can be argued that Big Pharma companies today are more centers of marketing and sales than drug discovery. The centers of drug discovery are increasingly in universities and smaller start-ups.
There have been many advances, including:
I am not sure there have been many factors that have hindered medical advances, apart from arrogance on the part of certain individuals. For example, company executives who have ignored requests from FDA to undertake clinical studies in a certain way, and then complain because their new drug applications were not accepted.
PharmTech: What are the top three innovations that have changed the industry the most over the past 40 years and why?
Moreton: My top three would be:
PharmTech: How have regulations and standards advanced or hindered advances?
Moreton: I do not believe that regulations have hindered advances. They may have hindered less scrupulous promotion of certain drug products, and they may have prevented dangerous or inadequately effective medicines from getting to market, but I regard those as pluses.
I think the regulations have actually saved lives, and promoted better research and testing.
PharmTech: What do you foresee for the next 10 years in pharma innovations, regulations, and/or markets?
Moreton: I think we will see oral delivery of peptide drugs, and this will open new areas of opportunity for the development of new treatments for diseases. We will likely see even more consolidation in all branches of the pharmaceutical sector. There will also be an accompanying further shift of drug discovery to smaller organizations with a concomitant growth in the contract sectors.
I think we may also see skills shortages in some areas as older people retire and there is no succession planning. Younger people are not able to get the training today that was available to me 45 years ago. Training is being increasingly cut back in all organizations.
Chris Moreton has been a member of Pharmaceutical Technology’s Editorial Advisory Board since 2003.
Vol. 41, No. 7
When referring to this article, please cite it as PharmTech, “Perspective: Big Pharma No Longer the Center of Innovation,” Pharmaceutical Technology 41 (7) 2017.